{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:44:30Z","timestamp":1789609470021,"version":"build-2803163510"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Osteoporosis, a widespread skeletal disorder with a substantial economic load, is characterized by increased porosity of the bones resulting in vulnerability to fractures. When activated, the canonical Wnt signaling pathway results in osteoblastogenesis and bone formation. A Wnt ligand forms a complex with low-density lipoprotein receptor-related proteins 5 and 6 (Lrp5\/6) and stimulates intracellular signaling cascades, leading to nuclear translocation of \u03b2-catenin and transcription of downstream molecules involved in osteoblast differentiation, maturation, and survival. Sclerostin (SOST), a glycoprotein produced by osteocytes, is an extracellular Wnt antagonist that blocks the binding of Wnt ligands to Lrp5\/6, preventing the activation of the pathway and osteoblast-mediated bone formation subsequently. Inhibition of SOST represents a new therapeutic paradigm for the treatment of osteoporosis. Monoclonal antibodies to SOST include romosozumab, blosozumab, and setrusumab. With its unique dual effect of increasing bone formation (anabolic action) and decreasing bone resorption, the Food and Drug Administration approved romosozumab, a promising new treatment for postmenopausal osteoporosis. Its efficacy and safety have been established in trials. However, patients at high risk of cardiovascular or cerebrovascular events should not be prescribed romosozumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jmh.jmh_106_20","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T09:26:24Z","timestamp":1642670784000},"page":"267-275","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Sclerostin Inhibition"],"prefix":"10.4103","volume":"12","author":[{"given":"Suruchi","family":"Aditya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Rattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20240906","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijem.IJEM_438_17","article-title":"Prevalence of osteoporosis in apparently healthy adults above 40 years of age in Pune City, India","volume":"22","author":"Kadam","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"key":"R2-5-20240906","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2147\/IJWH.S54623","article-title":"Epidemiology and treatment of osteoporosis in women: An Indian perspective","volume":"7","author":"Khadilkar","year":"2015","journal-title":"Int J Womens Health"},{"key":"R3-5-20240906","first-page":"108","article-title":"Preventable risk factors for osteoporosis in postmenopausal women: Systematic review and meta-analysis","volume":"7","author":"Thulkar","year":"2016","journal-title":"J Midlife Health"},{"key":"R4-5-20240906","first-page":"117","article-title":"Prevalence of osteoporosis in peri- and post-menopausal women in slum areas of Mumbai, India","volume":"9","author":"Shaki","year":"2018","journal-title":"J Midlife Health"},{"key":"R5-5-20240906","first-page":"84","article-title":"Prevalence of osteoporosis among vulnerable adults residing in the northeastern region of India: A preliminary report from a tertiary care referral hospital","volume":"9","author":"Borgohain","year":"2017","journal-title":"J OrthopTraumatol Rehabil"},{"key":"R6-5-20240906","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.mjafi.2016.09.007","article-title":"Osteoporosis among household women: A growing but neglected phenomenon","volume":"74","author":"Hiremath","year":"2018","journal-title":"Med J Armed Forces India"},{"key":"R7-5-20240906","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.afos.2018.03.003","article-title":"An updated hip fracture projection in Asia: The Asian Federation of Osteoporosis Societies study","volume":"4","author":"Cheung","year":"2018","journal-title":"Osteoporos Sarcopenia"},{"key":"R8-5-20240906","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"R9-5-20240906","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00198-019-05104-5","article-title":"Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: Results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)","volume":"30","author":"Hiligsmann","year":"2019","journal-title":"Osteoporos Int"},{"key":"R10-5-20240906","doi-asserted-by":"crossref","first-page":"R145","DOI":"10.1530\/JME-18-0173","article-title":"Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin","volume":"62","author":"Rachner","year":"2019","journal-title":"J Mol Endocrinol"},{"key":"R11-5-20240906","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.3390\/jcm9113439","article-title":"Anti-sclerostin antibodies in osteoporosis and other bone diseases","volume":"9","author":"Fabre","year":"2020","journal-title":"J Clin Med"},{"key":"R12-5-20240906","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1302\/2058-5241.4.180018","article-title":"Molecular understanding of pharmacological treatment of osteoporosis","volume":"4","author":"Tanaka","year":"2019","journal-title":"EFORT Open Rev"},{"key":"R13-5-20240906","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1759720X16670154","article-title":"Bone modeling and remodeling: Potential as therapeutic targets for the treatment of osteoporosis","volume":"8","author":"Langdahl","year":"2016","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R14-5-20240906","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jor.24170","article-title":"Cellular biology of fracture healing","volume":"37","author":"Bahney","year":"2019","journal-title":"J Orthop Res"},{"key":"R15-5-20240906","first-page":"96","article-title":"Clinical practice guidelines on postmenopausal osteoporosis: *An executive summary and recommendations \u2013 Update 2019-2020","volume":"11","author":"Meeta","year":"2020","journal-title":"J Midlife Health"},{"key":"R16-5-20240906","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jot.2015.08.004","article-title":"Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review","volume":"4","author":"Suen","year":"2016","journal-title":"J Orthop Translat"},{"key":"R17-5-20240906","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/js.2018-00118","article-title":"Osteoanabolic agents for osteoporosis","volume":"2","author":"Haas","year":"2018","journal-title":"J Endocr Soc"},{"key":"R18-5-20240906","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"R19-5-20240906","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/ijms20010083","article-title":"Anabolic therapies in osteoporosis and bone regeneration","volume":"20","author":"Russow","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R20-5-20240906","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","article-title":"Osteoporosis treatment: Recent developments and ongoing challenges","volume":"5","author":"Khosla","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R21-5-20240906","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fendo.2020.00165","article-title":"WNT signaling and bone: Lessons from skeletal dysplasias and disorders","volume":"11","author":"Huybrechts","year":"2020","journal-title":"Front Endocrinol (Lausanne"},{"key":"R22-5-20240906","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/0972-124X.145785","article-title":"Sclerostin and occlusion: A brief review","volume":"19","author":"Bansal","year":"2015","journal-title":"J Indian Soc Periodontol"},{"key":"R23-5-20240906","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.17219\/acem\/68739","article-title":"Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders","volume":"26","author":"Pietrzyk","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"R24-5-20240906","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","article-title":"Role and mechanism of action of sclerostin in bone","volume":"96","author":"Delgado-Calle","year":"2017","journal-title":"Bone"},{"key":"R25-5-20240906","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11255-018-2050-3","article-title":"Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients","volume":"51","author":"Pietrzyk","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"R26-5-20240906","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00296-015-3294-1","article-title":"Serum sclerostin is decreased following vitamin D treatment in young vitamin D-deficient female adults","volume":"35","author":"Cidem","year":"2015","journal-title":"Rheumatol Int"},{"key":"R27-5-20240906","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bone.2017.04.005","article-title":"Kinetic reconstruction reveals time-dependent effects of romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys","volume":"101","author":"Boyce","year":"2017","journal-title":"Bone"},{"key":"R28-5-20240906","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"R29-5-20240906","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s10354-019-00721-5","article-title":"Romosozumab: A novel bone anabolic treatment option for osteoporosis?","volume":"170","author":"Kerschan-Schindl","year":"2020","journal-title":"Wien Med Wochenschr"},{"key":"R30-5-20240906","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: The foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R31-5-20240906","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: Results of the frame extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"key":"R32-5-20240906","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"R33-5-20240906","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"R34-5-20240906","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-5-20240906","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: Results of a randomized phase 2a trial","volume":"32","author":"Glorieux","year":"2017","journal-title":"J Bone Miner Res"},{"key":"R36-5-20240906","doi-asserted-by":"crossref","first-page":"6217286","DOI":"10.1155\/2016\/6217286","article-title":"Sclerostin antibody therapy for the treatment of osteoporosis: Clinical prospects and challenges","volume":"2016","author":"MacNabb","year":"2016","journal-title":"J Osteoporos"},{"key":"R37-5-20240906","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"R38-5-20240906","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1759720X18775936","article-title":"The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis","volume":"10","author":"Solling","year":"2018","journal-title":"Ther Adv Musculoskel Dis"},{"key":"R39-5-20240906","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","article-title":"Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis","volume":"130","author":"Lv","year":"2020","journal-title":"Bone"},{"key":"R40-5-20240906","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s40265-020-01364-2","article-title":"Assessment of cardiovascular safety of anti-osteoporosis drugs","volume":"80","author":"Fuggle","year":"2020","journal-title":"Drugs"},{"key":"R42-5-20240906","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: A randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R43-5-20240906","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yrtph.2016.08.010","article-title":"Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study","volume":"81","author":"Chouinard","year":"2016","journal-title":"Regul Toxicol Pharmacol"},{"key":"R45-5-20240906","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40273-020-00965-9","article-title":"An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis","volume":"39","author":"Li","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"R46-5-20240906","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/8755122520967632","article-title":"Romosozumab: A novel agent in the treatment for postmenopausal osteoporosis","volume":"37","author":"Miller","year":"2021","journal-title":"J Pharm Technol"},{"key":"R47-5-20240906","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.clinthera.2017.05.348","article-title":"A model for assessing the clinical and economic benefits of bone-forming agents for reducing fractures in postmenopausal women at high, near-term risk of osteoporotic fracture","volume":"39","author":"O\u2019Hanlon","year":"2017","journal-title":"Clin Ther"},{"key":"R48-5-20240906","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1177\/1060028018798034","article-title":"Cost-effectiveness analysis of sequential treatment of abaloparatide followed by alendronate versus teriparatide followed by alendronate in postmenopausal women with osteoporosis in the United States","volume":"53","author":"Le","year":"2019","journal-title":"Ann Pharmacother"},{"key":"R49-5-20240906","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00198-020-05780-8","article-title":"Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden","volume":"32","author":"S\u00f6reskog","year":"2021","journal-title":"Osteoporos Int"},{"key":"R50-5-20240906","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24290","article-title":"Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: A systematic review and economic evaluation","volume":"24","author":"Davis","year":"2020","journal-title":"Health Technol Assess"},{"key":"R51-5-20240906","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int"}],"container-title":["Journal of Mid-life Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jmh.JMH_106_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:54:17Z","timestamp":1787756057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jmh.JMH_106_20"}},"subtitle":["A Novel Target for the Treatment of Postmenopausal Osteoporosis"],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jmh.jmh_106_20","relation":{},"ISSN":["0976-7800"],"issn-type":[{"value":"0976-7800","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}